Abbott, the largest manufacturer of baby formula in the USA, has cooperated with the FDA and CDC in conducting a thorough investigation. Today we are told that all investigating parties have concluded that no bacteria-tainted baby formula originated from the Abbott facility.
In a long series of eleven different tweets (which are worth reading through), Abbott affirms that: “a comprehensive investigation by Abbott, FDA and CDC found no evidence that our formulas caused infant illnesses.” Despite these conclusive findings, the Abbott plant still remains closed at the behest of the FDA.
Abbott appears to be another victim of the disproportionate targeting by the FDA of the few remaining domestic manufacturers of FDA-regulated products. Since Covid-19, the FDA still hasn’t fully resumed inspections of drug-manufacturing plants in China and India. Instead, the many inspectors otherwise sitting idle have focused their ire on the few remaining domestic FDA-regulated manufacturing plants. Shutting down FDA-regulated facilities always seems to happen a lot faster than reopening them, even if FDA accusations are unfounded — as Abbott has abundantly made clear.
Roy Mathews of the Alliance for Innovation and Infrastructure writes about high diesel prices:
It was only five months ago that Secretary of Energy Jennifer Granholm laughed at Bloomberg host Tom Keene’s question about increasing domestic oil production, calling it “hilarious.”
No one’s laughing now.